West Pharmaceutical Services, Inc. (NYSE: WST) Stock Competitors & Peer Comparison
See WST's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for WST and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| WST | $328.20 | -7.67% | 23.2B | 41.19 | $7.97 | +0.26% |
| BDX | $156.36 | +2.22% | 56.6B | 11.62 | $13.45 | +2.39% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.39% |
| MDLN | $38.75 | +2.98% | 32.8B | 45.06 | $0.86 | N/A |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| COO | $70.31 | +0.11% | 13.7B | 15.42 | $4.56 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.39% |
| BAX | $22.40 | +3.37% | 11.6B | 10.77 | $2.08 | +0.89% |
| ATR | $132.36 | +2.61% | 8.4B | 23.13 | $5.72 | +1.43% |
| AVTR | $11.44 | +0.79% | 7.8B | 13.46 | $0.85 | N/A |
Stock Comparison
Becton, Dickinson and Company (NYSE: BDX)
WST vs BDX Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, BDX has a market cap of 56.6B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while BDX trades at $156.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas BDX's P/E ratio is 11.62. In terms of profitability, WST's ROE is +0.19%, compared to BDX's ROE of +0.05%. Regarding short-term risk, WST is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for WST.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
WST vs BDXA Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas BDXA's P/E ratio is 45.70. In terms of profitability, WST's ROE is +0.19%, compared to BDXA's ROE of +0.05%. Regarding short-term risk, WST is more volatile compared to BDXA. This indicates higher risk in terms of short-term price fluctuations for WST.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
WST vs MDLN Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, MDLN has a market cap of 32.8B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while MDLN trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas MDLN's P/E ratio is 45.06. In terms of profitability, WST's ROE is +0.19%, compared to MDLN's ROE of +0.07%. Regarding short-term risk, WST is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for WST.Check MDLN's competition here
Hologic, Inc. (NASDAQ: HOLX)
WST vs HOLX Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas HOLX's P/E ratio is 31.54. In terms of profitability, WST's ROE is +0.19%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, WST is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for WST.Check HOLX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
WST vs COO Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, COO has a market cap of 13.7B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while COO trades at $70.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas COO's P/E ratio is 15.42. In terms of profitability, WST's ROE is +0.19%, compared to COO's ROE of +0.03%. Regarding short-term risk, WST is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for WST.Check COO's competition here
Becton, Dickinson and Company (NYSE: BDXB)
WST vs BDXB Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas BDXB's P/E ratio is 7.60. In terms of profitability, WST's ROE is +0.19%, compared to BDXB's ROE of +0.05%. Regarding short-term risk, WST is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for WST.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
WST vs BAX Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, BAX has a market cap of 11.6B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while BAX trades at $22.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas BAX's P/E ratio is 10.77. In terms of profitability, WST's ROE is +0.19%, compared to BAX's ROE of -0.16%. Regarding short-term risk, WST is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for WST.Check BAX's competition here
AptarGroup, Inc. (NYSE: ATR)
WST vs ATR Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, ATR has a market cap of 8.4B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while ATR trades at $132.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas ATR's P/E ratio is 23.13. In terms of profitability, WST's ROE is +0.19%, compared to ATR's ROE of +0.14%. Regarding short-term risk, WST is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for WST.Check ATR's competition here
Avantor, Inc. (NYSE: AVTR)
WST vs AVTR Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, AVTR has a market cap of 7.8B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while AVTR trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas AVTR's P/E ratio is 13.46. In terms of profitability, WST's ROE is +0.19%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, WST is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for WST.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
WST vs RGEN Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, RGEN has a market cap of 7.4B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while RGEN trades at $131.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas RGEN's P/E ratio is 73.31. In terms of profitability, WST's ROE is +0.19%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, WST is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for WST.Check RGEN's competition here
Teleflex Incorporated (NYSE: TFX)
WST vs TFX Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, TFX has a market cap of 5.8B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while TFX trades at $132.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas TFX's P/E ratio is 12.32. In terms of profitability, WST's ROE is +0.19%, compared to TFX's ROE of -0.28%. Regarding short-term risk, WST is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for WST.Check TFX's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
WST vs BLCO Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, BLCO has a market cap of 5.8B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while BLCO trades at $16.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas BLCO's P/E ratio is 24.88. In terms of profitability, WST's ROE is +0.19%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, WST is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for WST.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
WST vs STVN Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, STVN has a market cap of 5.4B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while STVN trades at $19.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas STVN's P/E ratio is 31.81. In terms of profitability, WST's ROE is +0.19%, compared to STVN's ROE of +0.10%. Regarding short-term risk, WST is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for WST.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
WST vs MMSI Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, MMSI has a market cap of 4.4B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while MMSI trades at $74.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas MMSI's P/E ratio is 19.01. In terms of profitability, WST's ROE is +0.19%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, WST is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for WST.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
WST vs ICUI Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while ICUI trades at $157.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas ICUI's P/E ratio is 19.66. In terms of profitability, WST's ROE is +0.19%, compared to ICUI's ROE of +0.02%. Regarding short-term risk, WST is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for WST.Check ICUI's competition here
Haemonetics Corporation (NYSE: HAE)
WST vs HAE Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, HAE has a market cap of 3.6B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while HAE trades at $78.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas HAE's P/E ratio is 15.86. In terms of profitability, WST's ROE is +0.19%, compared to HAE's ROE of +0.11%. Regarding short-term risk, WST is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for WST.Check HAE's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
WST vs XRAY Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, XRAY has a market cap of 2.6B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while XRAY trades at $12.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas XRAY's P/E ratio is 9.04. In terms of profitability, WST's ROE is +0.19%, compared to XRAY's ROE of -0.41%. Regarding short-term risk, WST is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for WST.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
WST vs LMAT Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, LMAT has a market cap of 2.2B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while LMAT trades at $95.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas LMAT's P/E ratio is 37.05. In terms of profitability, WST's ROE is +0.19%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, WST is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for WST.Check LMAT's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
WST vs PLSE Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, PLSE has a market cap of 2.1B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while PLSE trades at $30.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas PLSE's P/E ratio is -27.48. In terms of profitability, WST's ROE is +0.19%, compared to PLSE's ROE of -0.87%. Regarding short-term risk, WST is more volatile compared to PLSE. This indicates higher risk in terms of short-term price fluctuations for WST.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
WST vs ATRC Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, ATRC has a market cap of 1.8B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while ATRC trades at $35.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas ATRC's P/E ratio is 1088.20. In terms of profitability, WST's ROE is +0.19%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, WST is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for WST.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
WST vs BLFS Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, BLFS has a market cap of 1.5B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while BLFS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas BLFS's P/E ratio is -141.85. In terms of profitability, WST's ROE is +0.19%, compared to BLFS's ROE of -0.03%. Regarding short-term risk, WST is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for WST.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
WST vs AZTA Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, AZTA has a market cap of 1.3B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while AZTA trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas AZTA's P/E ratio is 60.82. In terms of profitability, WST's ROE is +0.19%, compared to AZTA's ROE of -0.11%. Regarding short-term risk, WST is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for WST.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
WST vs KMTS Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, KMTS has a market cap of 1.2B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while KMTS trades at $21.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas KMTS's P/E ratio is -8.92. In terms of profitability, WST's ROE is +0.19%, compared to KMTS's ROE of -0.59%. Regarding short-term risk, WST is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for WST.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
WST vs STAA Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, STAA has a market cap of 1.2B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while STAA trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas STAA's P/E ratio is 41.02. In terms of profitability, WST's ROE is +0.19%, compared to STAA's ROE of -0.06%. Regarding short-term risk, WST is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for WST.Check STAA's competition here
QuidelOrtho Corporation (NASDAQ: QDEL)
WST vs QDEL Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, QDEL has a market cap of 1.1B. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while QDEL trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas QDEL's P/E ratio is 11.98. In terms of profitability, WST's ROE is +0.19%, compared to QDEL's ROE of -0.56%. Regarding short-term risk, WST is more volatile compared to QDEL. This indicates higher risk in terms of short-term price fluctuations for WST.Check QDEL's competition here
Atrion Corporation (NASDAQ: ATRI)
WST vs ATRI Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas ATRI's P/E ratio is 64.50. In terms of profitability, WST's ROE is +0.19%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, WST is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for WST.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
WST vs ANGO Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, ANGO has a market cap of 561.7M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while ANGO trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas ANGO's P/E ratio is -34.85. In terms of profitability, WST's ROE is +0.19%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, WST is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for WST.Check ANGO's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
WST vs NNNN Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, NNNN has a market cap of 441.5M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while NNNN trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas NNNN's P/E ratio is 145.38. In terms of profitability, WST's ROE is +0.19%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, WST is more volatile compared to NNNN. This indicates higher risk in terms of short-term price fluctuations for WST.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
WST vs OSUR Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, OSUR has a market cap of 273.3M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas OSUR's P/E ratio is -4.78. In terms of profitability, WST's ROE is +0.19%, compared to OSUR's ROE of -0.21%. Regarding short-term risk, WST is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for WST.Check OSUR's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
WST vs SMTI Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, SMTI has a market cap of 234.2M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while SMTI trades at $25.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas SMTI's P/E ratio is -426.00. In terms of profitability, WST's ROE is +0.19%, compared to SMTI's ROE of -2.46%. Regarding short-term risk, WST is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for WST.Check SMTI's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
WST vs UTMD Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, UTMD has a market cap of 213.8M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while UTMD trades at $67.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas UTMD's P/E ratio is 19.86. In terms of profitability, WST's ROE is +0.19%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, WST is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for WST.Check UTMD's competition here
InfuSystem Holdings, Inc. (AMEX: INFU)
WST vs INFU Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, INFU has a market cap of 183.9M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while INFU trades at $9.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas INFU's P/E ratio is 23.97. In terms of profitability, WST's ROE is +0.19%, compared to INFU's ROE of +0.14%. Regarding short-term risk, WST is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for WST.Check INFU's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
WST vs KRMD Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, KRMD has a market cap of 175.9M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while KRMD trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas KRMD's P/E ratio is -95.75. In terms of profitability, WST's ROE is +0.19%, compared to KRMD's ROE of -0.14%. Regarding short-term risk, WST is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for WST.Check KRMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
WST vs PDEX Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, PDEX has a market cap of 175.4M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while PDEX trades at $54.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas PDEX's P/E ratio is 19.34. In terms of profitability, WST's ROE is +0.19%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, WST is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for WST.Check PDEX's competition here
Microbot Medical Inc. (NASDAQ: MBOT)
WST vs MBOT Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, MBOT has a market cap of 77.9M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while MBOT trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas MBOT's P/E ratio is -6.58. In terms of profitability, WST's ROE is +0.19%, compared to MBOT's ROE of -0.22%. Regarding short-term risk, WST is more volatile compared to MBOT. This indicates higher risk in terms of short-term price fluctuations for WST.Check MBOT's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
WST vs AKYA Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas AKYA's P/E ratio is -1.34. In terms of profitability, WST's ROE is +0.19%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, WST is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for WST.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
WST vs STSS Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, STSS has a market cap of 58.4M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while STSS trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas STSS's P/E ratio is -0.02. In terms of profitability, WST's ROE is +0.19%, compared to STSS's ROE of -1.66%. Regarding short-term risk, WST is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for WST.Check STSS's competition here
Daxor Corporation (NASDAQ: DXR)
WST vs DXR Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, DXR has a market cap of 52.7M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while DXR trades at $10.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas DXR's P/E ratio is 27.33. In terms of profitability, WST's ROE is +0.19%, compared to DXR's ROE of +0.22%. Regarding short-term risk, WST is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for WST.Check DXR's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
WST vs OMIC Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas OMIC's P/E ratio is -0.58. In terms of profitability, WST's ROE is +0.19%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, WST is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for WST.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
WST vs IGAP Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas IGAP's P/E ratio is -10.52. In terms of profitability, WST's ROE is +0.19%, compared to IGAP's ROE of -0.86%. Regarding short-term risk, WST is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for WST.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
WST vs NEPH Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, NEPH has a market cap of 38.6M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while NEPH trades at $3.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas NEPH's P/E ratio is 50.86. In terms of profitability, WST's ROE is +0.19%, compared to NEPH's ROE of +0.08%. Regarding short-term risk, WST is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for WST.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
WST vs MLSS Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, MLSS has a market cap of 34.5M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while MLSS trades at $0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas MLSS's P/E ratio is -6.50. In terms of profitability, WST's ROE is +0.19%, compared to MLSS's ROE of -1.66%. Regarding short-term risk, WST is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for WST.Check MLSS's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
WST vs POCI Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, POCI has a market cap of 33.8M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while POCI trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas POCI's P/E ratio is -6.07. In terms of profitability, WST's ROE is +0.19%, compared to POCI's ROE of -0.37%. Regarding short-term risk, WST is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for WST.Check POCI's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
WST vs SDC Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas SDC's P/E ratio is -0.03. In terms of profitability, WST's ROE is +0.19%, compared to SDC's ROE of -1.96%. Regarding short-term risk, WST is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for WST.Check SDC's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
WST vs HBIO Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, HBIO has a market cap of 27.3M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while HBIO trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas HBIO's P/E ratio is -16.81. In terms of profitability, WST's ROE is +0.19%, compared to HBIO's ROE of -0.73%. Regarding short-term risk, WST is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for WST.Check HBIO's competition here
Invacare Corporation (NYSE: IVC)
WST vs IVC Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas IVC's P/E ratio is -0.79. In terms of profitability, WST's ROE is +0.19%, compared to IVC's ROE of -0.46%. Regarding short-term risk, WST is more volatile compared to IVC. This indicates higher risk in terms of short-term price fluctuations for WST.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
WST vs RVP Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while RVP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas RVP's P/E ratio is -2.06. In terms of profitability, WST's ROE is +0.19%, compared to RVP's ROE of -0.08%. Regarding short-term risk, WST is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for WST.Check RVP's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
WST vs ZJYL Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, ZJYL has a market cap of 16M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while ZJYL trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas ZJYL's P/E ratio is 12.75. In terms of profitability, WST's ROE is +0.19%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, WST is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for WST.Check ZJYL's competition here
Femasys Inc. (NASDAQ: FEMY)
WST vs FEMY Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, FEMY has a market cap of 11.2M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while FEMY trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas FEMY's P/E ratio is -10.25. In terms of profitability, WST's ROE is +0.19%, compared to FEMY's ROE of -2.58%. Regarding short-term risk, WST is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for WST.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
WST vs RGNT Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, RGNT has a market cap of 7.8M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while RGNT trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas RGNT's P/E ratio is -0.08. In terms of profitability, WST's ROE is +0.19%, compared to RGNT's ROE of N/A. Regarding short-term risk, WST is more volatile compared to RGNT. This indicates higher risk in terms of short-term price fluctuations for WST.Check RGNT's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
WST vs NSTG Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas NSTG's P/E ratio is -0.03. In terms of profitability, WST's ROE is +0.19%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, WST is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for WST.Check NSTG's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
WST vs NXGL Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, NXGL has a market cap of 4M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while NXGL trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas NXGL's P/E ratio is -1.13. In terms of profitability, WST's ROE is +0.19%, compared to NXGL's ROE of -0.70%. Regarding short-term risk, WST is more volatile compared to NXGL. This indicates higher risk in terms of short-term price fluctuations for WST.Check NXGL's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
WST vs POAI Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas POAI's P/E ratio is -0.03. In terms of profitability, WST's ROE is +0.19%, compared to POAI's ROE of -107.05%. Regarding short-term risk, WST is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for WST.Check POAI's competition here
Lucyd, Inc (NASDAQ: LUCY)
WST vs LUCY Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, LUCY has a market cap of 2.6M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while LUCY trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas LUCY's P/E ratio is -0.39. In terms of profitability, WST's ROE is +0.19%, compared to LUCY's ROE of -0.83%. Regarding short-term risk, WST is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for WST.Check LUCY's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
WST vs MHUA Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas MHUA's P/E ratio is 0.25. In terms of profitability, WST's ROE is +0.19%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, WST is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for WST.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
WST vs NXGLW Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, NXGLW has a market cap of 1.8M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while NXGLW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas NXGLW's P/E ratio is -0.06. In terms of profitability, WST's ROE is +0.19%, compared to NXGLW's ROE of -0.70%. Regarding short-term risk, WST is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for WST.Check NXGLW's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
WST vs GMVD Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas GMVD's P/E ratio is -0.01. In terms of profitability, WST's ROE is +0.19%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, WST is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for WST.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
WST vs GMVDW Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas GMVDW's P/E ratio is N/A. In terms of profitability, WST's ROE is +0.19%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, WST is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for WST.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
WST vs AVGR Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas AVGR's P/E ratio is -0.05. In terms of profitability, WST's ROE is +0.19%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, WST is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for WST.Check AVGR's competition here
Lucyd, Inc (NASDAQ: LUCYW)
WST vs LUCYW Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas LUCYW's P/E ratio is -0.00. In terms of profitability, WST's ROE is +0.19%, compared to LUCYW's ROE of -0.83%. Regarding short-term risk, WST is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for WST.Check LUCYW's competition here
GlucoTrack, Inc. (NASDAQ: GCTK)
WST vs GCTK Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, GCTK has a market cap of 165.2K. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while GCTK trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas GCTK's P/E ratio is -0.01. In terms of profitability, WST's ROE is +0.19%, compared to GCTK's ROE of -5.82%. Regarding short-term risk, WST is less volatile compared to GCTK. This indicates lower risk in terms of short-term price fluctuations for WST.Check GCTK's competition here
Invuity, Inc. (NASDAQ: IVTY)
WST vs IVTY Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas IVTY's P/E ratio is -3.80. In terms of profitability, WST's ROE is +0.19%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, WST is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for WST.Check IVTY's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
WST vs ATRS Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas ATRS's P/E ratio is 14.95. In terms of profitability, WST's ROE is +0.19%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, WST is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for WST.Check ATRS's competition here
Apria, Inc. (NASDAQ: APR)
WST vs APR Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, APR has a market cap of 0. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas APR's P/E ratio is 22.59. In terms of profitability, WST's ROE is +0.19%, compared to APR's ROE of +9.81%. Regarding short-term risk, WST is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for WST.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
WST vs IIN Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, IIN has a market cap of 0. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas IIN's P/E ratio is 226.45. In terms of profitability, WST's ROE is +0.19%, compared to IIN's ROE of -0.00%. Regarding short-term risk, WST is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for WST.Check IIN's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
WST vs HRC Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, HRC has a market cap of 0. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas HRC's P/E ratio is 41.92. In terms of profitability, WST's ROE is +0.19%, compared to HRC's ROE of +0.14%. Regarding short-term risk, WST is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for WST.Check HRC's competition here
Analogic Corporation (NASDAQ: ALOG)
WST vs ALOG Comparison July 2026
West Pharmaceutical Services, Inc. (NYSE: WST) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, WST stands at 23.2B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, WST is priced at $328.20 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
WST currently has a P/E ratio of 41.19, whereas ALOG's P/E ratio is 40.93. In terms of profitability, WST's ROE is +0.19%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, WST is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for WST.Check ALOG's competition here